Cannabinoids and bone: Endocannabinoids modulate human osteoclast function in vitro

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2584-2597

  Whyte, Lauren S ^a   Ford, L ^a   Ridge, S A ^a   Cameron, G A ^a   Rogers, M J ^a   Ross, R A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

2 AG; AEA; Bone; Cannabinoid; CB 1; CB 2; Endocannabinoid; LPS; Osteoclast

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; F ACTIN; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MONOCYTE; OSTEOCLAST; OSTEOLYSIS; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

ANIMALS; ARACHIDONIC ACIDS; BONE AND BONES; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; GLYCERIDES; HUMANS; MICE; MICE, INBRED C57BL; MONOCYTES; OSTEOBLASTS; OSTEOCLASTS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RHO GTP-BINDING PROTEINS; RNA, MESSENGER;

EID: 84859049109     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01519.x     Document Type: Article

References (44)

1. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL (1997). Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 100: 1557-1565. (Pubitemid 27425783)
2. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM et al. (2001). Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142: 760-766. (Pubitemid 32222425)
4. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008). Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20 (Suppl. 1): 69-74. (Pubitemid 351552679)
5. Bab I, Zimmer A, Melamed E (2009). Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 41: 560-567.
6. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A et al. (1998). Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92: 3605-3615. (Pubitemid 28525186)
7. Chellaiah MA (2005). Regulation of actin ring formation by rho GTPases in osteoclasts. J Biol Chem 280: 32930-32943. (Pubitemid 41368343)
8. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D et al. (2001). Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276: 48213-48222.
9. Di Marzo V, Petrosino S (2007). Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18: 129-140. (Pubitemid 46412082)
10. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al. (1999).Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267. (Pubitemid 29385890)
11. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulatiosubpopulations. Eur J Biochem 232: 54-61.
12. Gokoh M, Kishimoto S, Oka S, Metani Y, Sugiura T (2005). 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. FEBS Lett 579: 6473-6478. (Pubitemid 41612170)
13. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
14. Idris AI (2008). Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News Perspect 21: 533-540.
15. Idris AI, Ralston SH (2010). Cannabinoids and bone: friend or foe? Calcif Tissue Int 87: 285-297.
16. Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D et al. (2009). Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metabolism 10: 139-147.
17. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA et al. (2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11: 774-779. (Pubitemid 41021210)
18. Jorda MA, Lowenberg B, Delwel R (2003). The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. Blood 101: 1336-1343. (Pubitemid 36182504)
19. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14: 3389-3396. (Pubitemid 41672123)
20. Karsak M, Malkin I, Toliat MR, Kubisch C, Nurnberg P, Zimmer A et al. (2009). The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. Hum Genet 126: 629-636.
21. Liu J, Batkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF et al. (2003). Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/ NF-kappaB independently of platelet-activating factor. J Biol Chem 278: 45034-45039. (Pubitemid 37377264)
22. McIntosh HH, Song C, Howlett AC (1998). CB1 cannabinoid receptor: cellular regulation and distribution in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 53: 163-173. (Pubitemid 28085452)
23. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B (1996). Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 64: 2371-2380. (Pubitemid 26226792)
24. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103: 696-701. (Pubitemid 43153088)
25. Pertwee RG, Ross RA (2002). Cannabinoid receptors and their ligands. [Review] [212 refs]. Prostaglandins Leukot Essent Fatty Acids 66: 101-121. (Pubitemid 34743589)
26. Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA (1998). Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51: 391-402. (Pubitemid 28078470)
27. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 1484-1495. (Pubitemid 41540004)
28. Rayman N, Lam KH, Laman JD, Simons PJ, Lowenberg B, Sonneveld P et al. (2004). Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol 172: 2111-2117. (Pubitemid 38182356)
29. Ross RA (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156-163.
30. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672. (Pubitemid 29087845)
31. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S et al. (2009). The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44: 476-484.
32. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101. (Pubitemid 350166046)
33. Saltel F, Destaing O, Bard F, Eichert D, Jurdic P (2004). Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell 15: 5231-5241. (Pubitemid 39564720)
34. Sharir H, Abood ME (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301-313.
35. Song C, Howlett AC (1995). Rat brain cannabinoid receptors are N-linked glycosylated proteins. Life Sci 56: 1983-1989.
36. Sophocleous A, Landao-Bassonga E, Van't Hof RJ, Idris AI, Ralston SH (2011). The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 152: 2141-2149.
37. Suda K, Woo JT, Takami M, Sexton PM, Nagai K (2002). Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J Cell Physiol 190: 101-108.
38. Take I, Kobayashi Y, Yamamoto Y, Tsuboi H, Ochi T, Uematsu S et al. (2005). Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146: 5204-5214. (Pubitemid 41653034)
39. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R et al. (2006). Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70: 786-792. (Pubitemid 44268435)
40. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A et al. (2008). The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 22: 285-294.
41. Taylor A, Rogers MJ, Tosh D, Coxon FP (2007). A novel method for efficient generation of transfected human osteoclasts. Calcif Tissue Int 80: 132-136. (Pubitemid 46294975)
42. Varga K, Wagner JA, Bridgen DT, Kunos G (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044. (Pubitemid 28359585)
43. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ et al. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511-16516.
44. Yamada Y, Ando F, Shimokata H (2007). Association of candidate gene polymorphisms with bone mineral density in communitydwelling Japanese women and men. Int J Mol Med 19: 791-801.